Grant: Engage Plus Grants Program
Université de Sherbrooke
$12,500.00
HARNESSING PEPTIDASE'S ACTIVE SITE TO DISRUPT PROTEIN INTERACTION
FY 2015-16
Summary
The interaction between the low-density lipoprotein receptor (LDLR) and the serine peptidase PCSK9 is
independent of the enzyme's catalytic activity, but is responsible for the down-regulation of this receptor. The
ultimate goal of Koff Pharma is to design molecules that will decrease LDLR degradation, thus promoting LDL
clearance. However, Koff needs partners to develop biochemical and functional assays to advance its R&D
effort. Our goal is to support the development of a PCSK9-LDLR interaction inhibitor. Our longstanding
expertise working with proteolytic enzymes offers an ideal opportunity for both our laboratory and Koff. We
propose that we can use the PCSK9's catalytic site as a tethering site for pharmacophors that will disrupt
PCSK9-LDLR interaction. The novelty of this approach is that the catalytic site will generate selectivity and
potency, and help addressing the 'last frontier' of medicinal chemistry that is protein-protein interactions.
However, as a proof of concept, we must demonstrate the feasibility of the approach, and new technologies
must be developed. Toward this goal, we propose two aims: 1) to develop a PCSK9 enzymatic assay, and to
identify a first generation hit inhibitor; 2) to establish a PCSK9-LDLR interaction functional assay in
hepatocytes. Sub-aims include the establishment of a non-enzymatic, label-free PCSK9 inhibitor screening
assay. Our group has developed extensive expertise in working with proteolytic enzymes by developing assays,
doing enzyme biochemistry, and protein engineering. Therefore, we are perfectly suited to assist Koff. This
industry-academic partnership will strengthen the capability of Koff to provide novel treatments and our ability
to perform cutting edge research in biochemistry. This project will also serve as a starting point for long-term
collaboration between parties, which will lead to the training of HQPs in Canada.
Program
Engage Plus Grants Program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
486965-2015
Name nom
Denault, JeanBernard
Department département
Pharmacologie
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
12500
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
1
Nb partie
1
Application title
HARNESSING PEPTIDASE'S ACTIVE SITE TO DISRUPT PROTEIN INTERACTION
Keyword
NSERC
Application summary
The interaction between the low-density lipoprotein receptor (LDLR) and the serine peptidase PCSK9 is
independent of the enzyme's catalytic activity, but is responsible for the down-regulation of this receptor. The
ultimate goal of Koff Pharma is to design molecules that will decrease LDLR degradation, thus promoting LDL
clearance. However, Koff needs partners to develop biochemical and functional assays to advance its R&D
effort. Our goal is to support the development of a PCSK9-LDLR interaction inhibitor. Our longstanding
expertise working with proteolytic enzymes offers an ideal opportunity for both our laboratory and Koff. We
propose that we can use the PCSK9's catalytic site as a tethering site for pharmacophors that will disrupt
PCSK9-LDLR interaction. The novelty of this approach is that the catalytic site will generate selectivity and
potency, and help addressing the 'last frontier' of medicinal chemistry that is protein-protein interactions.
However, as a proof of concept, we must demonstrate the feasibility of the approach, and new technologies
must be developed. Toward this goal, we propose two aims: 1) to develop a PCSK9 enzymatic assay, and to
identify a first generation hit inhibitor; 2) to establish a PCSK9-LDLR interaction functional assay in
hepatocytes. Sub-aims include the establishment of a non-enzymatic, label-free PCSK9 inhibitor screening
assay. Our group has developed extensive expertise in working with proteolytic enzymes by developing assays,
doing enzyme biochemistry, and protein engineering. Therefore, we are perfectly suited to assist Koff. This
industry-academic partnership will strengthen the capability of Koff to provide novel treatments and our ability
to perform cutting edge research in biochemistry. This project will also serve as a starting point for long-term
collaboration between parties, which will lead to the training of HQPs in Canada.